These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11049046)

  • 1. Colorectal cancer chemotherapy: irinotecan.
    Rougier P; Mitry E
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):138-43. PubMed ID: 11049046
    [No Abstract]   [Full Text] [Related]  

  • 2. [Irinotecan in colorectal cancer].
    Pozzo C; Cassano A; Barone C
    Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approves irinotecan as first-line therapy for colorectal cancer.
    Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
    [No Abstract]   [Full Text] [Related]  

  • 4. [Proceedings of the 3rd National Conference of Medical Oncology. Irinotecan: present and future. Napoli, Italy, 5 November 2001].
    Tumori; 2001; 87(6):A29-37. PubMed ID: 11995704
    [No Abstract]   [Full Text] [Related]  

  • 5. The changing face of chemotherapy in colorectal cancer.
    Waters J; Cunningham D
    Br J Cancer; 2001 Jan; 84(1):1-7. PubMed ID: 11139304
    [No Abstract]   [Full Text] [Related]  

  • 6. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camptothecins: new enthusiasm for an old drug.
    Rowe PM
    Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
    Tsunoda T
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
    [No Abstract]   [Full Text] [Related]  

  • 9. The development of camptothecin analogs in childhood cancers.
    Bomgaars L; Berg SL; Blaney SM
    Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
    Terauchi F
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():175-8. PubMed ID: 15535228
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical and clinical trials of topoisomerase inhibitors.
    Saijo N
    Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan hydrochloride.
    Wilkinson K
    Clin J Oncol Nurs; 2001; 5(4):179-80, 184. PubMed ID: 12690622
    [No Abstract]   [Full Text] [Related]  

  • 13. Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
    O'Reilly S; Rowinsky EK
    Hematol Oncol Clin North Am; 1997 Aug; 11(4):721-58. PubMed ID: 9257153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of topoisomerase I inhibitors in anticancer treatment.
    Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
    Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan in esophageal cancer.
    Enzinger PC; Ilson DH
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):26-30. PubMed ID: 11200145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
    Liu X; Xu W
    Pharmacogenomics; 2014 Jun; 15(9):1171-4. PubMed ID: 25141892
    [No Abstract]   [Full Text] [Related]  

  • 20. The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction.
    Ajani JA
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):17-8. PubMed ID: 11200142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.